Annex 5, WHO Technical Report Series 1010, 2018
Djibuti et al. BMC Public Health (2015) 15:427 DOI 10.1186/s12889-015-1760-z
Orientations provisoires, 27 mai 2021
Reviewed Essential Medicines List July 2021
Technical Report
AIDS Medicines and diagnostics service
July 2015
Este documento presenta modelos de algoritmos que permiten investigar por métodos bacteriológicos a los pacientes para el diagnóstico de tuberculosis (TB), TB asociada al Virus de Inmunodeficiencia Humana (TB-HIV) y TB drogorresistente (TBDR).
Technical Report
AIDS Medicines and diagnostics service
September 2016
Global COVID-19 Clinical Platform: Case Record Form for suspected cases of Multisystem inflammatory syndrome (MIS) in children and adolescents temporally related to COVID-19
The pre-clinical pipeline shows more innovation and diversity, with 252 agents being developed to treat WHO priority pathogens.
However, these products are in the very early stages of development and still need to be proven effective and safe. The optimistic scenario, the report indicates, is for... the first two to five products to become available in about 10 years.
more
Training module on malaria control
n October 2019, WHO convened the first meeting of the Buruli ulcer laboratory network (BU-LABNET) in Yaoundé, Cameroon, bringing together 11 laboratories from nine countries at the Pasteur Centre of Cameroon (CPC), the network’s Coordinating Centre. The network was formally established at th...is meeting (1) and its members were those present. The objective of BU LABNET is to improve diagnosis of Buruli ulcer based on polymerase chain reaction (PCR) using standardized testing protocols, involving external quality assurance programmes and sharing knowledge among member laboratories.
more
Ebola Virus Disease Outbreak Response Plan in West Africa Annex 3
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
The aim of the meeting was to broaden the network’s initiatives. Preliminary work involved integrating laboratory testing for skin NTDs other than Buruli ulcer, such as cutaneous leishmaniasis, mycetoma, leprosy and yaws, while extending the network’s reach to encompass additional laboratories.
Guidelines for the treatment of human African trypanosomiasis. Web Annex A. Commissioned by WHO Cochrane Response
This guideline provides updated, evidence-informed guidance on the percentage of total fat in the diet to reduce the risk of unhealthy weight gain.
This guideline is intended for a wide audience involved in the development, design and implementation of policies and programmes in nutrition and pub...lic health. This guideline includes a recommended level of total fat intake which can be used by policy-makers and programme managers to address various aspects of dietary fat in their populations through a range of policy actions and public health interventions.
The guidance in this guideline replaces previous WHO guidance on total fat intake, including that from the 1989 WHO Study Group on Diet, Nutrition and the Prevention of Chronic Diseases and the 2002 Joint WHO/FAO Expert Consultation on Diet, Nutrition and the Prevention of Chronic Diseases. The guidance in this guideline should be considered in the context of that from other WHO guidelines on healthy diets.
more